CLARITY Trial: Oral Cladribine for Relapsing-Remitting MS

This presentation delves into the CLARITY Trial, exploring the efficacy and safety of oral cladribine as a short-course treatment for multiple sclerosis (MS). Key sections cover MS disease challenges, the trial's Phase 3 design, and findings, including a 57.6% reduction in relapse rates and decreased MRI lesion activity. Safety concerns, such as lymphocytopenia, and the advantages of patient adherence to oral therapies are discussed. The focus is on the need for innovative treatments...